Literature DB >> 15325132

Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.

Barbra LaRue1, Elizabeth Hogg, Abhay Sagare, Suzana Jovanovic, Lawrence Maness, Calvin Maurer, Rashid Deane, Berislav V Zlokovic.   

Abstract

The role of transport exchanges of neuroactive solutes across the blood-brain barrier (BBB) is increasingly recognized. To take full advantage of genetically altered mouse models of neurodegenerative disorders for BBB transport studies, we adapted a brain perfusion technique to the mouse. During a carotid brain perfusion with a medium containing sheep red blood cells and mock plasma, the physiological parameters in the arterial inflow, regional cerebral blood flow (14C-iodoantipyrine autoradiography), ultrastructural integrity of the tissue, barrier to lanthanum, brain water content, energy metabolites and lactate levels remain unchanged. Amyloid-beta peptides (Abeta) were iodinated by lactoperoxidase method. Non-oxidized mono-iodinated Abeta monomers were separated by HPLC (as confirmed by MALDI-TOF spectrometry) and used in transport measurements. Transport of intact 125I-Abeta40 across the BBB was time- and concentration-dependent in contrast to negligible 14C-inulin uptake. In 5-6 months old Alzheimer's Tg2576 mice, Abeta40 BBB transport was increased by >eight-fold compared to age-matched littermate controls, and was mediated via the receptor for advanced glycation endproducts. We conclude the present arterial brain perfusion method provides strictly controlled environment in cerebral microcirculation suitable for examining transport of rapidly and slowly penetrating molecules across the BBB in normal and transgenic mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15325132     DOI: 10.1016/j.jneumeth.2004.04.026

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  25 in total

1.  A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease.

Authors:  Rashid Deane; Itender Singh; Abhay P Sagare; Robert D Bell; Nathan T Ross; Barbra LaRue; Rachal Love; Sheldon Perry; Nicole Paquette; Richard J Deane; Meenakshisundaram Thiyagarajan; Troy Zarcone; Gunter Fritz; Alan E Friedman; Benjamin L Miller; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

Review 2.  Amyloid beta: structure, biology and structure-based therapeutic development.

Authors:  Guo-Fang Chen; Ting-Hai Xu; Yan Yan; Yu-Ren Zhou; Yi Jiang; Karsten Melcher; H Eric Xu
Journal:  Acta Pharmacol Sin       Date:  2017-07-17       Impact factor: 6.150

3.  Transport of prion protein across the blood-brain barrier.

Authors:  W A Banks; Sandra M Robinson; R Diaz-Espinoza; A Urayama; C Soto
Journal:  Exp Neurol       Date:  2009-05-05       Impact factor: 5.330

4.  Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice.

Authors:  Ryusuke Takechi; Susan Galloway; Menuka Pallebage-Gamarallage; Cheryl Wellington; Russell Johnsen; John Charles Mamo
Journal:  Histochem Cell Biol       Date:  2009-02-19       Impact factor: 4.304

Review 5.  The role of the cell surface LRP and soluble LRP in blood-brain barrier Abeta clearance in Alzheimer's disease.

Authors:  R Deane; A Sagare; B V Zlokovic
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 6.  Mouse models of neurological disorders: a view from the blood-brain barrier.

Authors:  William A Banks
Journal:  Biochim Biophys Acta       Date:  2009-10-29

7.  Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease.

Authors:  Alaa H Abuznait; Courtney Cain; Drury Ingram; David Burk; Amal Kaddoumi
Journal:  J Pharm Pharmacol       Date:  2011-06-11       Impact factor: 3.765

8.  Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system.

Authors:  Robert D Bell; Abhay P Sagare; Alan E Friedman; Gurrinder S Bedi; David M Holtzman; Rashid Deane; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2006-11-01       Impact factor: 6.200

Review 9.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

10.  Amyloid-beta colocalizes with apolipoprotein B in absorptive cells of the small intestine.

Authors:  Susan Galloway; Ryusuke Takechi; Menuka M S Pallebage-Gamarallage; Satvinder S Dhaliwal; John C L Mamo
Journal:  Lipids Health Dis       Date:  2009-10-22       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.